
Voting in the Senate on a bill that would provide funding for the US semiconductor industry as part of efforts to improve competitiveness with China could begin as early as Tuesday, Senate Majority Leader Chuck Schumer has been telling lawmakers, a source familiar with the issue said on Thursday.
The source said the bill, in addition to $52 billion in chip subsidies, would include, at a minimum, an investment tax credit from the “Facilitating American-Built Semiconductors (FABS) Act,” legislation intended to provide incentives for construction, expansion or modernization of semiconductor fabrication plants in the United States.
The planned legislation is a smaller version of a bill the Senate passed in June 2021 that included the $52 billion for chip subsidies and authorized another $200 billion to boost U.S. scientific and technological innovation to compete with China. The House of Representatives never took up that bill, instead passing its own version in February that is similar to the Senate measure but also includes a number of trade proposals.
The comments about Schumer’s plans were consistent with what Commerce Secretary Gina Raimondo told Reuters in an interview on Wednesday. She said lawmakers appeared to be moving to carve off $52 billion in semiconductor chips manufacturing subsidies from a larger bill on boosting U.S. competitiveness with China.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas